Page 123 - 《中国药房》2025年12期
P. 123

[ 5 ]  ABDULLAHI  M,ANNIBALE  B,CAPOCCIA  D,et  al.   [17]  杨少鹏,李志婷,徐力东. 幽门螺杆菌根除率非药物影响
              The eradication of Helicobacter pylori is affected by body   因素的 Logistic 回归分析[J]. 华北理工大学学报(医学
              mass  index(BMI)[J].  Obes  Surg,2008,18(11):1450-  版),2018,20(2):98-101.
              1454.                                          [18]  王坷娜,孙艳,耿利利,等. 幽门螺杆菌初次根除失败风
          [ 6 ]  刘倩,蒋晓玲,严权,等. 幽门螺旋杆菌感染根除率现状                       险评分系统的构建[J]. 浙江医学,2024,46(1):15-19,32.
              及其影响因素分析[J]. 系统医学,2023,8(15):42-45.            [19]  胡智华,牛小平. 皖南地区幽门螺杆菌根除失败的相关
          [ 7 ]  曾宪涛,刘慧,陈曦,等 . Meta 分析系列之四:观察性研                   危险因素分析[J]. 右江民族医学院学报,2019,41(6):
              究的质量评价工具[J]. 中国循证心血管医学杂志,2012,                      629-632,641.
              4(4):297-299.                                  [20]  苏卫仙,代金玉,史增辉. 幽门螺杆菌根除率非药物影响
          [ 8 ]  BROUTET N,TCHAMGOUÉ S,PEREIRA E,et al. Risk      因素 Logistic 回归分析及对策[J]. 河北医科大学学报,
              factors  for  failure  of  Helicobacter  pylori  therapy:results   2019,40(7):777-780.
              of an individual data analysis of 2 751 patients[J]. Aliment   [21]  袁龙良,辛毅,王启之. 幽门螺旋杆菌根除失败的影响因
              Pharmacol Ther,2003,17(1):99-109.                   素分析[J]. 蚌埠医学院学报,2019,44(11):1497-1499.
          [ 9 ]  DARRAJ  M A.  Eradication  rate  and  factors  influencing   [22]  金玉琳. 难治性幽门螺杆菌根除的影响因素分析[J]. 系
              Helicobacter  pylori  infection  clearance  using  standard   统医学,2023,8(16):95-97,101.
              triple therapy at a single centre in Jazan region,Saudi Arabia:  [23]  陆福山,钟月圆,刘秋杰,等. 影响幽门螺旋杆菌感染消
              a retrospective study[J]. Int J Gen Med,2024,17:2627-  化性溃疡患者病原菌根除效果的因素调查[J]. 热带医学
              2634.                                               杂志,2022,22(8):1130-1132,1157.
          [10]  PEÑA-GALO  E,GOTOR  J,HARB  Y,et  al.  Socioeco‐  [24]  齐尔旋,周丽雅. 阿莫西林和克拉霉素最小抑菌浓度折
              nomic and demographic factors associated with failure in   点对含其幽门螺杆菌根除方案疗效的影响[J]. 中华消化
              Helicobacter  pylori  eradication  using  the  standard  triple   杂志,2021,41(6):385-391.
              therapy[J].  Gastroenterol  Hepatol  Bed  Bench,2021,14  [25]  GRAHAM D Y,LU H,YAMAOKA Y. A report card to
              (1):53-58.                                          grade Helicobacter pylori therapy[J]. Helicobacter,2007,
          [11]  JAKA H,MUELLER A,KASANG C,et al. Predictors of    12(4):275-278.
              triple  therapy  treatment  failure  among  H.  pylori  infected   [26]  TAKARA Y,ENDO H,NAKANO R,et al. Smoking and
              patients attending at a tertiary hospital in Northwest Tanzania:  drinking did not increase the failure of therapeutic Helico‐
              a prospective study[J]. BMC Infect Dis,2019,19(1):447.  bacter  pylori  eradication  by  vonoprazan,clarithromycin,
          [12]  KHADIM S,MUHAMMAD I N,ALAM T,et al. Predic‐       and amoxicillin[J]. Digestion,2019,99(2):172-178.
              tors of successful first-line Helicobacter pylori eradication   [27]  HUGUET J M,FERRER-BARCELÓ L,SUÁREZ P,et al.
              with fluoroquinolones in Pakistan:a prospective explora‐  Role  of  compliance  in  Helicobacter  pylori  eradication
              tion  of  demographic  and  clinical  factors[J].  Antibiotics  treatment:results  of  the  European  Registry  on  H.  pylori
              (Basel),2024,13(3):211.                             management [J].United European Gastroenterol J,2024,
          [13]  LEE J Y,KIM N,KIM M S,et al. Factors affecting first-  12(6):691-704.
              line  triple  therapy  of  Helicobacter  pylori  including   [28]  丁松泽,杜奕奇,陆红,等. 中国居民家庭幽门螺杆菌感
              CYP2C19  genotype  and  antibiotic  resistance[J].  Dig  Dis   染的防控和管理专家共识:2021 年[J]. 胃肠病学,2022,
              Sci,2014,59(6):1235-1243.                           27(12):734-746.
          [14]  ZHU X J,LI S B,LIU Y,et al. Current situation and risk   [29]  HU Y,ZHU Y,LU N H. Primary antibiotic resistance of
              factors  for  Helicobacter  pylori  eradication  failure  in   Helicobacter  pylori  in  China[J].  Dig  Dis  Sci,2017,62
              Northwest  China:a  real-world  evidence  study[J].  Chin   (5):1146-1154.
              Med J(Engl),2023,136(4):488-490.               [30]  陈晨,吴滢,华娴,等. 宿主因素对幽门螺杆菌感染患者
          [15]  吴蓉,周刚 . 幽门螺杆菌三联根除疗法影响因素的 Lo‐                      菌株耐药性的影响[J]. 协和医学杂志,2024,15(5):
              gistic 回归分析[J]. 中国全科医学,2011,14(26):2981-            1091-1099.
              2983.                                                         (收稿日期:2024-12-03  修回日期:2025-04-29)
          [16]  张振宇. 含铋剂四联疗法对幽门螺杆菌根除效果的影响                                                         (编辑:陈 宏)
              因素分析[J]. 华夏医学,2020,33(6):156-159.







          中国药房  2025年第36卷第12期                                              China Pharmacy  2025 Vol. 36  No. 12    · 1529 ·
   118   119   120   121   122   123   124   125   126   127   128